PARP1 and ovarian carcinoma: PARP inhibitors (PARPis) including olaparib (Lynparza®; AstraZeneca Pharmaceuticals, Cambridge, UK), rucaparib (Rubraca®; Clovis Oncology, Inc., Boulder, CO, USA) and niraparib (Zejula®; GlaxoSmithKline, Brentford, Middlesex, UK) are small molecule inhibitors of PARP that have been approved by the US Food and Drug Administration (FDA), and other regulatory authorities worldwide, for women with ovarian cancer under certain conditions, including as maintenance therapy.